I
Insight Molecular Diagnostics Inc. (IMDX)
NCM – Real vaqt narxi. Valyuta: USD
4.98
+0.07 (1.43%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
4.98
+0.07 (1.43%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Insight Molecular Diagnostics Inc. Qo'shma Shtatlar va xalqaro miqyosda aniq diagnostika kompaniyasi sifatida faoliyat yuritadi. Kompaniya laboratoriya tomonidan ishlab chiqarilgan testlar, tadqiqotlar uchun mo'ljallangan to'plamlar va klinik test to'plamlarini ishlab chiqadi va tijoratlashtiradi. U saratonni davolashning bir siklidan so'ng rivojlanishni erta aniqlaydigan qonga asoslangan monitoring vositasi bo'lgan DetermaCNI; va immunoterapiyaga javobni bashorat qilish uchun o'simta mikro-muhitini baholaydigan gen ekspressiyasi testi bo'lgan DetermaIOni ishlab chiqmoqda. Kompaniya, shuningdek, potentsial bemorlarni ro'yxatga olish uchun yangi PCR asosidagi o'lchov platformasidan foydalangan holda dd-cfDNAni o'lchashga mo'ljallangan qon testi bo'lgan GraftAssureCore testini; donor tomonidan hosil qilingan erkin hujayrali DNKni o'lchaydigan transplantatsiya monitoringi uchun GraftAssureIQni; va buyrak transplantatsiyasidan keyin plazmada donor tomonidan hosil qilingan erkin hujayrali DNK darajasini markazlashtirilmagan transplantatsiya monitoringini amalga oshiruvchi GraftAssureDxni taklif etadi, bu esa standart klinik baholashlar bilan birgalikda test o'tkazilgan vaqtda allograft rad etish ehtimolini baholashga yordam beradi. Bundan tashqari, u biomarkerlarni kashf qilish, tahlilni loyihalash va ishlab chiqish, klinik sinovlarni qo'llab-quvvatlash va turli xil biomarker testlari uchun test xizmatlarini taqdim etadi. Kompaniya Bio-Rad Laboratories, Inc. bilan Bio-Radning ddPCR asboblari va reagentlaridan foydalangan holda tadqiqotlar uchun mo'ljallangan va in vitro diagnostik transplantatsiya mahsulotlarini ishlab chiqish va tijoratlashtirish bo'yicha hamkorlik shartnomasiga ega. Kompaniya ilgari OncoCyte Corporation nomi bilan tanilgan va 2025 yil iyun oyida Insight Molecular Diagnostics Inc. nomini olgan. Insight Molecular Diagnostics Inc. 2009 yilda tashkil etilgan va Neshvill, Tennessi shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Ekkehard Schutz M.D., Ph.D. | Chief Science Officer |
| Dr. Michael D. West Ph.D. | Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. |
| Dr. Paul R. Billings FACP, M.D., Ph.D. | Consulting Chief Medical Officer |
| Mr. James Liu | VP of Accounting, Treasurer, Controller & Principal Accounting Officer |
| Mr. Joshua Riggs | President, CEO & Director |
| Mr. Peter Hong | VP, General Counsel & Secretary |
| Mr. Steven Tahmooressi | Vice President of Marketing |
| Mr. Yuh-Min Chiang Ph.D. | Chief Technology Officer |
| Ms. Andrea Susan James | Chief Financial Officer |
| Ms. Sandra O'Donald | Senior Vice President of Business Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | 8-K | form8-k.htm |
| 2026-03-26 | 8-K | form8-k.htm |
| 2026-03-26 | 10-K | imdx-20251231.htm |
| 2026-02-26 | 8-K | form8-k.htm |
| 2026-02-12 | 8-K | form8-k.htm |
| 2026-02-11 | 8-K | form8-k.htm |
| 2025-11-10 | 8-K | form8-k.htm |
| 2025-10-02 | 8-K | form8-k.htm |
| 2025-09-19 | 8-K | form8-k.htm |
| 2025-08-18 | S-8 | forms-8.htm |